HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Infectious Disease
Surveillance report supports safety of JYNNEOS vaccine for mpox prevention
Is the mpox vaccine safe? New safety report offers reassurance.
A U.S. surveillance report indicates the JYNNEOS vaccine for mpox prevention appears safe. The report does not provide specific population d…
A new safety report confirms the JYNNEOS mpox vaccine maintains its established safety profile as more people receive the shot.
CDC
Apr 5, 2026
Infectious Disease
CDC adapted smallpox preparedness and HIV programs for US mpox response
CDC used smallpox and HIV programs to respond to mpox outbreak in the US
A report describes how US public health systems adapted existing smallpox preparedness frameworks and HIV prevention infrastructure for the …
The CDC fought the mpox outbreak by adapting smallpox and HIV programs already in place, using existing tools to tackle a new health threat.
CDC
Apr 5, 2026
Infectious Disease
Mpox cluster emerges among previously vaccinated individuals in Chicago investigation
Mpox cluster emerges in Chicago among people who had received the vaccine
A field investigation in Chicago documented the emergence of an mpox cluster primarily affecting persons previously vaccinated against mpox.…
Chicago officials report a mpox cluster among people who had already received the vaccine, showing immunity isn't perfect for everyone.
CDC
Apr 5, 2026
Infectious Disease
JYNNEOS vaccine effectiveness against mpox infection studied in New York City surveillance
Did the mpox vaccine work in New York City? A new report looks for answers.
A New York City surveillance report examined JYNNEOS vaccine effectiveness against diagnosed mpox infection. No specific effectiveness resul…
New York City officials rolled out the JYNNEOS vaccine to stop mpox spread, but a new surveillance report has not yet released specific resu…
CDC
Apr 5, 2026
Pediatrics
Phase II
Phase 2 trial assesses JYNNEOS vaccine in adolescents for monkeypox prevention
Is the monkeypox vaccine safe and effective for teenagers?
A Phase 2 open-label, non-placebo controlled trial evaluated the standard subcutaneous JYNNEOS regimen in 315 vaccinia-naïve adolescents (12…
A new study is looking at whether the standard monkeypox vaccine works for adolescents. Researchers compared immune responses and side effec…
CT.gov
Apr 4, 2026
Infectious Disease
Clade Ib mpox cases diagnosed in Kenya from July 2024 to February 2025
What does the new mpox outbreak in Kenya mean for people there?
A descriptive outbreak report details the diagnosis of clade Ib mpox cases in Kenya between July 2024 and February 2025. The case series pro…
Kenya is tracking a new clade Ib mpox outbreak from July 2024 through February 2025, separate from the 2022 global strain.
CDC
Apr 4, 2026
Infectious Disease
Tecovirimat distribution reported during Los Angeles County mpox outbreak
How did Los Angeles County distribute mpox treatment during the outbreak?
A report describes tecovirimat distribution during the 2022-23 mpox outbreak in Los Angeles County. No clinical outcomes, safety data, or co…
A new report details how Los Angeles County distributed the antiviral drug tecovirimat to treat mpox patients during the 2022-23 outbreak.
CDC
Apr 4, 2026
Pediatrics
Mpox cases in US children linked to household contacts or caregivers in descriptive report
How are young children getting mpox? A new report points to home exposure.
A descriptive case series of children aged ≤12 years with mpox in the United States found cases were exposed by household contacts or caregi…
A new report shows young children with mpox often caught the virus from household contacts or caregivers inside their homes.
CDC
Apr 4, 2026
OB/GYN & Women's Health
Case series finds no adverse reaction to tecovirimat in four pregnant persons with mpox
Is the mpox treatment safe for pregnant people? Early data shows no adverse reactions.
A U.S. surveillance case series of mpox in cisgender women reported no adverse reaction to tecovirimat in four treated pregnant persons. No …
Early data on pregnant people treated for mpox shows no adverse reactions to the antiviral drug tecovirimat, offering a small but valuable p…
CDC
Apr 4, 2026
Allergy & Immunology
ACIP Recommends JYNNEOS Vaccine for Adults at Risk During Mpox Outbreaks
Health Panel Recommends Mpox Vaccine for At-Risk Adults During Outbreaks
A 2023 ACIP recommendation report advises use of the JYNNEOS vaccine for persons aged 18 years and older at risk for mpox during an outbreak…
U.S. health experts now recommend the JYNNEOS vaccine for adults at risk of mpox during outbreaks to help protect public health.
CDC
Apr 3, 2026
Pediatrics
Meta-analysis
Paediatric mpox PCR positivity rates range from 6.95% to 35.6% in global systematic review
How does mpox affect children? New review finds wide range in positive tests.
A systematic review and meta-analysis of 22 studies on paediatric mpox globally found PCR positivity rates ranging from 6.95% in non-endemic…
Mpox test positivity in children ranges from 7% to 36%, with younger kids facing higher risks of severe complications like fever and skin le…
Apr 2, 2026